Trends That Advanced CRISPR Therapies in 2021
Jan. 19, 2022
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Mammoth Biosciences
Main focus: Diagnostics and treatment of genetic diseases using novel Cas enzymes
Company stage: Commercial (diagnostics), pre-clinical (therapeutics)
Diseases: COVID-19 (diagnostic), otherwise undisclosed
Genome editing tool: Cas14 and CasΦ
Funding stage: Private
Location: Brisbane CA, USA
Website: https://mammoth.bio/
Partners: Vertex Pharmaceuticals, Merck, GlaxoSmithKline
Mammoth Biosciences is focused on discovering novel CRISPR systems for diagnostics and therapeutic applications. The company is currently developing CRISPR-Cas12, Cas13, Cas14 and CasΦ, which may provide advantages over currently used systems. The DETECTRTM platform is based on these CRISPR systems, and has so far been applied out for SARS-CoV-2 testing. Although the lead programmes remain undisclosed, the company also develops its CRISPR systems for the treatment of genetic diseases. The company is co-founded by Nobel Laureate, Jennifer Doudna.
